DP
LPCN icon

Diadema Partners’s Lipocine LPCN Stock Holding History

Diadema Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$400K Sell
50,000
-210,939
-81% -$1.84M 0.07% 116
2025
Q4 		$2.1M Buy
+260,939
New +$878K 0.36% 64

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Diadema Partners's LPCN Position: Q1 2026 in Review

Diadema Partners reduced its Lipocine (LPCN) stake by 81% in Q1 2026, selling an estimated $1.84M and leaving 50,000 shares worth $400K. The position accounts for 0.07% of the portfolio, ranked #116.

Diadema Partners first reported a position in LPCN in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.1M in Q4 2025. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Diadema Partners held 50,000 shares of Lipocine worth $400K as of Q1 2026.
  • Diadema Partners sold 210,939 Lipocine shares in Q1 2026, an estimated $1.84M.
  • Lipocine made up 0.07% of Diadema Partners's portfolio in Q1 2026, its #116 holding.
  • Diadema Partners first reported a position in Lipocine in Q4 2025 and has held it in 2 quarters since.
  • Diadema Partners's Lipocine position peaked at $2.1M in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.